BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme
By Denny Jacob
BioMarin Pharmaceutical received a subpoena from the U.S. Justice Department for certain documents regarding sponsored testing programs related to vimizim and naglazyme.
The biotechnology company said it has produced the requested documents in response to the subpoena and is cooperating fully, according to a regulatory filing. It added that it is unable to make any assurance regarding the outcome of the investigation by the DOJ and the potential impact such an investigation would have on aspects of the company.
A representative for the DOJ didn't immediately respond to a request for comment.
Vimizim is a treatment of MPS IVA, a lysosomal storage disorder. Naglazyme is a treatment for patients with MPS VI, a life-threatening genetic disease.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 26, 2024 14:23 ET (19:23 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks